建模晚期卵巢癌患者的治疗结局:优化治疗选择检测的预期获益
本研究用微模拟模型预测晚期上皮性卵巢癌(EOC)患者采用假设性检测分诊至初次肿瘤细胞减灭术(PCS)或新辅助化疗后间歇性肿瘤细胞减灭术(NACT+ICS)相比标准诊疗的预期寿命(LE)增益,发现即使检测完美,LE增益也仅1.2个月,且检测正确识别可切除患者的能力比正确分诊不可切除患者更重要。
要点
- 即使检测完美,LE增益也仅1.2个月(67.6 vs 66.4个月)。
- 检测需高概率正确识别PCS可切除患者,此特性比正确分诊不可切除患者更重要。
- 结果对 underlying disease 在PCS时可切除的患者比例敏感。
核心结论
- 旨在分诊晚期EOC患者的诊断检测可能仅对LE产生 modest 影响。
研究设计与样本
- 微模拟模型,预测IIIC期EOC患者的LE,比较标准诊疗策略与假设检测策略,并进行敏感性分析评估参数不确定性。
主要发现
- 完美检测策略 vs 标准诊疗策略的LE为67.6个月 vs 66.4个月,LE增益为1.2个月。
- 检测需高概率正确识别PCS可切除患者才能优于标准诊疗,此特性比正确分诊不可切除患者至NACT+ICS更重要。
- 结果对 underlying disease 在PCS时可切除的患者比例敏感。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: For patients with advanced stage epithelial ovarian cancer (EOC), substantial emphasis has been placed on diagnostic tests that can discern which of two treatment options - primary cytoreductive surgery (PCS) or neoadjuvant chemotherapy followed by interval cytoreductive surgery (NACT+ICS) - optimizes patient-level outcomes. Our goal was to project potential life expectancy (LE) gains that could be achieved by use of such a test. METHODS: We developed a microsimulation model to project LE for patients with stage IIIC EOC. We compared: a "standard-of-care" strategy, in which patients were triaged to PCS vs. NACT+ICS based on current clinical practice; and a "test" strategy, in which patients were triaged based on results of a hypothetical test. We identified those test performance characteristics for which the test strategy outperformed the standard-of-care strategy, from a LE standpoint. Effects of parameter uncertainty were evaluated in sensitivity analysis. RESULTS: Even with a perfect test, the LE gain was modest (LE with test vs. standard-of-care strategy=67.6 vs. 66.4months; LE gain=1.2months). In order to outperform the standard-of-care, the test had to have a high probability of correctly identifying "resectable" patients at PCS (i.e. those for whom complete or optimal cytoreduction would be possible); this test property was more important than correct triage of unresectable patients to NACT+ICS. Results were sensitive to the proportion of patients whose underlying disease was resectable at PCS. CONCLUSION: Diagnostic tests that are designed to triage patients with advanced stage EOC will likely have only a modest effect on LE.
引用
- Weaver DT, Raphel TJ, Melamed A, et al. Modeling treatment outcomes for patients with advanced ovarian cancer: Projected benefits of a test to optimize treatment selection. Gynecol Oncol. 2018. PMID: 29486993. doi:10.1016/j.ygyno.2018.02.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。